20/20 OptimEyes Technologies
About
20/20 OptimEyes Technologies has developed a mucoadhesive nanoparticle (MNP) drug delivery platform that enhances API solubility and significantly improves the durability of drug exposure at mucosal surfaces. The company is actively advancing and partnering the platform across multiple therapeutic areas, with active programs in ophthalmology, respiratory infections, and bladder oncology, and is seeking both strategic partnerships and investment to accelerate development and maximize platform value.
The technology has been validated in ophthalmic applications, with successful preclinical studies in glaucoma, dry eye, and uveitis, demonstrating its ability to improve efficacy, patient compliance, and lifecycle potential of small-molecule therapeutics. 20/20 OptimEyes is engaging partners for co-development, licensing, and application of the platform to novel or repurposed APIs targeting mucosal tissues.
What is your business/industry sector?